Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Supreet Sahai

Neurology Los Angeles, CA Medical Doctor

NPI 1538587159 CMS profile 1718830

127 S San Vicente Blvd, Suite A6600, Los Angeles, CA 90048

Open in the dashboard

General payments

$4,951

203 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Supreet Sahai of Los Angeles, CA is reported in the CMS Open Payments database as having received $4,951 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,221 47
2024 General $1,158 52
2023 General $820 20
2022 General $859 48
2021 General $771 35
2019 General $121 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Supreet Sahai
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Supreet Sahai were reported at $1,221. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Supreet Sahai Neurology median Middle half National median
2019 $121 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $771 $438 $104–$2,547 $132
2022 $859 $442 $103–$2,388 $149
2023 $820 $464 $119–$2,312 $160
2024 $1,158 $468 $119–$2,323 $164
2025 $1,221 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,322 72 payments
  2. Teva Pharmaceuticals USA, Inc. $565 32 payments
  3. Pfizer Inc. $550 35 payments
  4. Natus Medical Incorporated $525 1 payment
  5. Abbott Laboratories $357 4 payments
  6. Lundbeck LLC $262 15 payments
  7. Axsome Therapeutics, Inc. $184 3 payments
  8. Biogen, Inc. $183 10 payments
  9. Neurocrine Biosciences, Inc. $173 1 payment
  10. Argenx US, Inc. $158 7 payments
  11. Other $671 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,346 201 payments
  2. Honoraria $525 1 payment
  3. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $1,061 55 payments
  2. NURTEC ODT $550 35 payments
  3. QULIPTA $541 27 payments
  4. ZAVZPRET $534 34 payments
  5. VYEPTI $224 12 payments
  6. INFINITY $199 3 payments
  7. AJOVY $195 12 payments
  8. Austedo XR $190 7 payments
  9. Symbravo $184 3 payments
  10. AUSTEDO $181 13 payments
  11. Other $1,564 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$34,576

Of which drugs: $3,039

Medicare patients

73

Average age 71

Services billed

900

43 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 56%
Diabetes 51%
Ischemic heart disease 25%
Depression 23%
Alzheimer's or dementia 19%
Chronic kidney disease 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 11 31 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $178
$178 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $173
$173 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $166
$166 — —
UBRELVY
  • AbbVie, Inc. $154
$154 — —
NURTEC ODT
  • PFIZER INC. $152
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record